Sarepta Therapeutics (SRPT): Cash Enough To Reach Profitability - Oppenheimer

November 1, 2016 7:38 AM EDT
Get Alerts SRPT Hot Sheet
Price: $31.02 -1.24%

Rating Summary:
    17 Buy, 10 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 18 | New: 11
Trade SRPT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Oppenheimer analyst, Michelle Gilson, reiterated her Outperform rating on shares of Sarepta Therapeutics (NASDAQ: SRPT) after the company reported 3Q16 financial results, ending the quarter with $395M in cash, which she estimates is sufficient to fund operations into profitability.

She views recent concerns over reimbursement of EXONDYS 51 (approved September 19) as overblown, given the early stage of the launch. She anticipates Sarepta will have 25 patients on EXONDYS 51 by YE2016, based on ~375M DMD patients covered by Cigna, Humana (ambulatory boys only) and United Health.

In 2H17. as payer negotiations stabilize and Sarepta's educational efforts begin to take hold, she anticipates a strong uptick in boys on therapy. No change to the price target of $76.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $39.24 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change

Related Entities


Add Your Comment